EssilorLuxottica Bets on AI-Powered Smart Glasses as Competition Intensifies 
Obamacare Premiums Set to Double in 2026 as Subsidy Expiration Looms Amid U.S. Shutdown 
Trump’s Approval of AI Chip Sales to China Triggers Bipartisan National Security Concerns 
SpaceX Insider Share Sale Values Company Near $800 Billion Amid IPO Speculation 
GameStop Misses Q3 Revenue Estimates as Digital Shift Pressures Growth 
China to Add Eli Lilly’s Mounjaro to National Health Insurance in 2025 
Coca-Cola’s Costa Coffee Sale Faces Uncertainty as Talks With TDR Capital Hit Snag 
Innovent’s Xinermei Intensifies Weight-Loss Drug Battle in China 
Air Force One Delivery Delayed to 2028 as Boeing Faces Rising Costs 
U.S. and Rwanda Sign $228 Million Health Partnership to Boost Self-Reliance 
FDA Pilot Program Eases Rules for Nicotine Pouch Makers 
Samsung SDI Secures Major LFP Battery Supply Deal in the U.S. 
Trump Administration to Launch Autism Initiatives Targeting Acetaminophen Use and New Treatment Options 
Mizuho Raises Broadcom Price Target to $450 on Surging AI Chip Demand 
Trello Outage Disrupts Users as Access Issues Hit Atlassian’s Work Management Platform 
Major Drugmakers Slash U.S. Prices and Sell Directly to Patients Amid Trump’s Push for Affordable Medicines 
Nvidia Develops New Location-Verification Technology for AI Chips 
German healthcare and materials company Merck KGaA (NSE:PROR) announced on Monday that it has agreed to acquire U.S.-based biotech firm SpringWorks Therapeutics in a deal valued at approximately $3.9 billion. The acquisition is aimed at strengthening Merck’s oncology business and expanding its pipeline of cancer therapies.
The Darmstadt-headquartered group said it will pay $47 per share in cash for SpringWorks, representing a premium over the company’s recent trading price. The deal assigns SpringWorks an equity value of $3.9 billion and an enterprise value of around $3.4 billion (3.0 billion euros) after adjusting for the biotech firm's cash reserves.
SpringWorks Therapeutics specializes in developing targeted therapies for severe rare diseases and cancers, with its lead product, nirogacestat, positioned to treat desmoid tumors. The acquisition will give Merck access to a promising late-stage oncology asset and enhance its long-term growth prospects in the competitive cancer treatment market.
This move aligns with Merck's strategic focus on innovation and expanding its specialty medicine portfolio. The transaction is expected to strengthen its presence in the U.S. biotech sector and accelerate the development of novel oncology solutions for patients worldwide.
The acquisition is subject to customary closing conditions, including regulatory approvals, and is expected to finalize later this year.
